Dear NF friends, families, and loved ones:

PLEASE FORWARD to family and friends we need everyones support.

Action is needed now to encourage Congress to vote against the Continuing Resolution (CR) that will be on the House floor as early as Tuesday. This bill significantly reduces funding for the Congressionally Directed Medical Research Programs (CDMRP), which includes the Neurofibromatosis Research Program (NFRP).

Your voice is now more important than ever.

Using a simple form on the NF Network website, we need you, your friends, family, and loved ones to be NF advocates and ask Congress to vote against the full year CR and enact a full year Defense Appropriations bill that fully funds the CDMRP and the NFRP.

Your representatives need to hear from YOU. Your personal contact: 

1. Shows members of Congress that there are many voters affected by NF
2. Requests that Congress fully fund medical research at the Department of Defense through the Congressionally Directed Medical Research Program, including the NFRP

If you’ve done this before, you know how easy it is. Simply enter your full name and mailing address – that’s it!

A letter is already written, and the system automatically identifies your representatives from your address; however, please feel free to include YOUR story as a part of your letter to your Congressional representatives. As a constituent, it is your voice that will encourage your Congressperson or Senator to take action. Instructions for personalizing your email are included with the letter.

Thank you for taking action today and being ONE VOICE for the NF community!

As early as this Tuesday, the House will be voting on a continuing resolution to fund government programs through the end of fiscal year 2025 (FY25). The proposed legislation, introduced in the House, cuts FY25 funding for the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP) from $1.509 billion to $650 million – a 57 percent cut from the FY24 enacted level. The Ovarian Cancer Research Program (OCRP) is housed within the CDMRP and has played a vital role in bringing about cutting-edge therapies and diagnostic tools for cancer patients since its inception in 1997. 

Currently Funded Research Programs

• Alcohol and Substance Use Disorders
• Alzheimer’s
• Amyotrophic Lateral Sclerosis
• Arthritis
• Autism
• Bone Marrow Failure
• Breast Cancer
• Chronic Pain Management
• Combat Readiness-Medical
• Duchenne Muscular Dystrophy
• Epilepsy
• Glioblastoma
• Gulf War Illness
• Hearing Restoration
• Joint Warfighter Medical
• Kidney Cancer
• Lung Cancer
• Lupus
• Melanoma
• Military Burn
• Multiple Sclerosis
• Neurofibromatosis
• Neurotoxin Exposure Treatment Parkinson’s
• Orthotics and Prosthetics Outcomes
• Ovarian Cancer
• Pancreatic Cancer
• Parkinson’s
• Peer Reviewed Cancer
• Peer Reviewed Medical
• Peer Reviewed Orthopaedic
• Prostate Cancer
• Rare Cancers
• Reconstructive Transplant Research
• Scleroderma
• Spinal Cord Injury
• Tick-Borne Disease
• Toxic Exposures
• Traumatic Brain Injury and Psychological Health
• Tuberous Sclerosis Complex
• Vision